Amine Sadok
Senior Director & Head Of the Induced Proximity Platform Amgen
Accomplished scientist with 10+ years of drug discovery experience in academia and biotech. Strong background in cancer biology, genetics, and protein homeostasis. Expertise in target identification, lead discovery, and building innovative technology platforms. Highly creative scientist with an entrepreneurial mindset and proven track record of leading and executing challenging drug discovery programs.
Seminars
Thursday 11th June 2026
Panel Discussion: Navigating Venture Capital Funding & Structuring Strategic Collaborations in South Korea to Accelerate Biotech Growth, Secure Investment & Expand Global Reach
9:00 am
- Understanding Korean venture capital expectations to tailor fundraising strategies, attract competitive capital and enable sustainable biotech scaling
- Identifying how recent deals highlight investor priorities for emerging modalities including novel ligases, non-oncology-targeted degraders, and DACs to guide platform positioning and increase funding success
- Examining how early-stage proof-of-concept studies validate technology, strengthen investor confidence, and accelerate pharma partnership commitments
- Discussing how to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your TPD candidate
Wednesday 10th June 2026
Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing
11:30 am
- Leveraging ultra-miniaturized microfluidics devices to facilitate unbiased RNA-seq screening of a biased E3-focused library to enable target-agnostic discovery of VHL MGDs
- Identifying dGEM3, a novel VHL molecular glue that targets the survival of motor neuron (SMN) complex member GEMIN3 for degradation
- Characterizing the GEMIN3 degron within its helicase ATP-binding domain and revealing how ternary complex kinetics impact degradation through cellular, biochemical, and biophysical assays
- Explaining how these findings provide insights into the re-programmability of VHL for novel targets using drug-like molecular glues
